Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Most Shorted Stocks
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Investors
Private Companies
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Careers
Contact Us
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
MCP for Agents
Advertise with Us
Top Online Brokers
Gold IRA Companies
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Most Shorted Stocks
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Center
Investors
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Gold IRA Review
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
STOK
Stock Latest News
Company Announcements
Stoke Therapeutics Charts Path From EMPEROR To Launch
15d ago
STOK
Premium
Ratings
Analyst Affirms Buy on Stoke Therapeutics as Phase 3 EMPEROR Trial Progress and Strong Cash Position Support Clear Path to 2028 Launch
15d ago
STOK
Premium
Ratings
Stoke Therapeutics: Buy Rating Reaffirmed with Strong Balance Sheet, Clinical Progress, and Unchanged $44 Price Target
15d ago
STOK
Premium
Ratings
Yaron Werber Reaffirms Buy on Strengthening Zorevunersen Outlook in Dravet Syndrome, Lifts Peak Sales View to $3B and Sets New $60 Price Target
15d ago
STOK
Premium
Ratings
Thomas Shrader Reaffirms Buy Rating on Zorevunersen Developer with Unchanged $39 Price Target, Citing Strong Phase 3 Outlook and Compelling Clinical Profile
15d ago
STOK
Premium
Ratings
Stoke Therapeutics: Strong Zorevunersen Trial Progress and Regulatory Visibility Support Buy Rating; Price Target Reaffirmed at $40
15d ago
STOK
Premium
The Fly
Stoke Therapeutics price target lowered to $58 from $60 at Canaccord
15d ago
STOK
Premium
Company Announcements
Stoke Therapeutics Expands ATM Equity Program for Funding
16d ago
8K
STOK
Premium
The Fly
Stoke Therapeutics reports Q2 EPS (93c), consensus (78c)
16d ago
STOK
Premium
Pre-Earnings
Stoke Therapeutics (STOK) Q2 Earnings Cheat Sheet
19d ago
STOK
Premium
The Fly
Stoke Therapeutics appoints McCauley as Chief Scientific Officer
1M ago
STOK
Premium
The Fly
Stoke Therapeutics initiated with a Buy at Goldman Sachs
1M ago
STOK
Premium
Company Announcements
Stoke Therapeutics Completes Enrollment in Phase 3 Dravet Trial
2M ago
8K
STOK
Premium
The Fly
Stoke Therapeutics completes enrollment of 162 patients in Phase 3 EMPEROR study
2M ago
STOK
Premium
Company Announcements
Stoke Therapeutics Stockholders Approve Directors and Governance Items
3M ago
8K
STOK
Premium
Ratings
Stoke Therapeutics: Buy Rating Reiterated as Phase 3 Dravet Program Advances; $60 Price Target Maintained
3M ago
STOK
Premium
Ratings
Analyst Reiterates Buy on Stoke Therapeutics, Maintains $40 Price Target on Robust Dravet Data and Phase 3 Progress
3M ago
STOK
Premium
Ratings
Werber Reiterates Buy on Strong EMPEROR Phase 3 Progress, Durable Zorevunersen Data and Solid Cash Runway Through 2028
3M ago
STOK
Premium
The Fly
Stoke Therapeutics reports Q1 EPS (79c), consensus (84c)
3M ago
STOK
Premium
Ratings
De-Risked Phase 3 Design and Durable Efficacy Support Buy Rating on Stoke Therapeutics’ Zorevunersen
4M ago
STOK
Premium
Ratings
Advancing Zorevunersen in Dravet Syndrome: Late‑Stage Trial Clarity and Regulatory Momentum Support Buy Rating on Stoke Therapeutics
4M ago
STOK
Premium
Company Announcements
Stoke Therapeutics Adds Veteran Leader to Board, R&D Oversight
4M ago
8K
STOK
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >
You need to enable JavaScript to run this app.
